Skip to main content

Comparison of the metabolic effects of long-term treatment with pindolol or atenolol by hypertensive patients

Cardiovascular Drugs and Therapy volume 1, pages 549–551 (1988)Cite this article

Summary

The effects of plasma lipids, blood glucose, and serum total cholesterol, LDL-cholesterol, VLDL-cholesterol, 6-month period were studied in 18 patients with essential hypertension.

There were no significant changes in the concentration of serum total cholesterol. LDL-cholesterol, VLDL-cholesterol, and triglycerides during treatment periods with pindolol or atenolol, although there was a tendency to higher triglyceride levels during atenolol treatment.

The serum HDL-cholesterol levels were significantly lower after 6 months of therapy with atenolol than before treatment, but HDL-cholesterol levels increased slightly during pindolol treatment. The ratio of HDL-cholesterol to total cholesterol decreased significantly during 6 months of treatment with atenolol.

Fasting blood glucose concentrations did not change significantly during 6 months of treatment with pindolol or atenolol, but during oral glucose tolerance test, blood glucose values at 60 min were raised after pindolol therapy. Serum insulin levels during oral glucose tolerance test at 120 min were decreased after pindolol therapy, but no significant changes were found in C-peptide levels during treatment periods.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Ames RP, Hill P. Increase in serum lipids during treatment of hypertension with chlorthalidone.Lancet 1976; 1:721–23.

    Google Scholar 

  2. Helgeland A, Hjermann I, Leren P, et al. High density lipoprotein cholesterol and antihypertensive drugs: The Oslo Study.Br Med J 1978; 2:403.

    Google Scholar 

  3. Day JL, Simpson N, Metcalfe J, Page RL. Metabolic consequences of atenolol and propranolol in treatment of essential hypertension.Br Med J 1979; 1:77–80.

    Google Scholar 

  4. Lehtonen A, Marniemi J. Effect of atenolol on plasma HDL cholesterol subfractions.Atherosclerosis 1984; 51:335–38.

    Google Scholar 

  5. Lehtonen A, Hietanen E, Marniemi J, et al. Effect of pindolol on serum lipids and lipid metabolizing enzymes.Br J Clin Pharmacol 1982; 13(Suppl 2):445–47.

    Google Scholar 

  6. Lehtonen A. Long-term effects of pindolol on plasma lipids, apoproteins A, blood glucose and serum insulin levels.Int J Clin Pharmacol Ther Toxic 1984; 22:269–272.

    Google Scholar 

  7. Lehtonen A. The effect of acebutolol on plasma lipids, blood glucose and serum insulin levels.Acta Med Scand 1984; 216:57–60.

    Google Scholar 

  8. Viikari J. Precipitation of plasma lipoproteins by PEG-6000 and its evaluation with electrophoresis and ultracentrifugation.Scand J Clin Lab Invest 1976; 36:265–268.

    Google Scholar 

  9. Beaumont JL, Carlson LA, Cooper GR, et al. Classification of hyperlipidemias and hyperlipoproteinaemias.Bull WHO 1970; 43:891–910.

    Google Scholar 

  10. Faber O, Binder C. C-peptide response to glucagon: a test for residual function in diabetes mellitus.Diabetes 1977; 26:605–10.

    Google Scholar 

  11. Lehtonen A, Viikari J. Long-term effect of sotalol on plasma lipids.Clin Sci 1979; 57:405–07.

    Google Scholar 

  12. Shaw J, England JDF, Hua ASP. Beta-blockers and plasma triglycerides.Br Med J 1978; 1:986.

    Google Scholar 

  13. Neasy A-J, Lowenstein J. Effect of prazosin, atenolol and thiazide diuretic on plasma lipids in patients with essential hypertension.Amer J Med 1986; 80 (Suppl 2A):94–99.

    Google Scholar 

  14. Rouffy J, Jaillaird J. Effects of two antihypertensive agents on lipids, lipoproteins and apoproteins A and B. Comparison of prazosin and atenolol.Amer J Med 1986; 80 (Suppl 2A):100–03.

    Google Scholar 

  15. England JDF, Simons LA, Gibson JC, Carlton M. The effect of metoprolol and atenolol on plasma high density in lipoprotein levels in man.Clin Exp Pharmacol Physiol 1980; 7:329–33.

    Google Scholar 

  16. Frishman WH, Michelson EL, Johnson BF, Poland MP. Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension.Amer J Med 1983; 75 (Suppl):54–67.

    Google Scholar 

  17. Rössner S, Weiner L. Atenolol and metoprolol—comparison of effects of blood pressure and serum lipoproteins and side effects.Eur J Clin Pharmacol 1984; 24:573–77.

    Google Scholar 

  18. Weinberger MH. Antihypertensive therapy and lipids: evidence, mechanisms, and implications.Arch Intern Med 1985; 145:1102–05.

    Google Scholar 

  19. Weidmann P, Uehlinger DE, Gerber A. Antihypertensive treatment and serum lipoproteins.J Hypertension 1985; 3:297–306.

    Google Scholar 

  20. Holm G, Johansson S, Vedin A, et al. The effect of betablockade on glucose tolerance and insulin release in adult diabetes.Acta Med Scand 1980; 208:187–91.

    Google Scholar 

Download references

Author information

Affiliations

  1. Department of Medicine, Turku City Hospital, SF-20700, Turku, Finland

    A. Lehtonen M.D.

Authors
  1. A. Lehtonen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lehtonen, A. Comparison of the metabolic effects of long-term treatment with pindolol or atenolol by hypertensive patients. Cardiovasc Drug Ther 1, 549–551 (1988). https://doi.org/10.1007/BF02125739

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02125739

Key words

  • atenolol
  • hypertension
  • pindolol
  • cholesterol
  • lipids
  • glucose